France's LEEM signs eco deal with govt

31 March 2009

France's research-based pharmaceutical association, the LEEM, has signed a convention on the progress to be made in the 2009-2011 period for the  pharmaceutical sector's support of Grenelle Environment Forum, a  tripartite assembly designed to create a policy consensus. Under the  terms of the deal, French drugmakers and the local units of foreign  pharmaceutical companies have pledged to take up five main elements of  the Forum.

First, the convention details ways in which manufacturers will reduce  climate-affecting gases and improve the energy conservation of the  sector. This will be achieved by scrapping fleets of vehicles and  replacing them with more environmentally-friendly cars, encouraging  car-pooling and Carbon Plans. Second, drugmakers promise to involve  employees in environmental efforts through training, including  sensitivity training and information programs. Third, the LEEM's 300  members will "continue to develop a sustained relationship with  stakeholders (patient associations, environmental protection groups,  etc) around issues of sustainable development and health care," the  group said. Fourth, the LEEM promises to adopt a "responsible  communication" strategy which limits environmental impacts. Finally,  the reinforcement of the public/private partnership over issues such as  the disposal of unused drugs, biohazardous waste, water pollution and  biodiversity protection.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight